Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab

Priti S. Hegde, Adrian M. Jubb, Dafeng Chen, Nicole F. Li, Yong Meng, Coen Bernaards, Rebecca Elliott, Stefan Scherer, Daniel S. ChenClinical 2012 · DOI

Abstract

In this comprehensive evaluation, pretreatment total circulating VEGF-A was prognostic for outcome in metastatic colorectal, lung, and renal cell cancers, but it was not predictive for bevacizumab-based treatment benefit.
BibTeX
@inproceedings{hegde2012predictive,
  author = {Priti S. Hegde and Adrian M. Jubb and Dafeng Chen and Nicole F. Li and Yong Meng and Coen Bernaards and Rebecca Elliott and Stefan Scherer and Daniel S. Chen},
  title = {{Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab}},
  booktitle = {Clinical},
  year = {2012},
  doi = {10.1158/1078-0432.ccr-12-2535},
}

Loading related content...

Figure